School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia.
Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, Cancer Care ServicesBuilding 34, Cnr. Bowen Bridge Rd and Butterfield St, Herston, Queensland, 4029, Australia.
Support Care Cancer. 2024 Nov 5;32(12):775. doi: 10.1007/s00520-024-08961-x.
Patients receiving treatment for solid tumours and haematological malignancies, among other acute and chronic health conditions, are highly dependent upon central venous access devices (CVADs) for administering chemotherapy and other complex therapies; thus, CVADs can meaningfully impact their health outcomes and experiences. This systematic review aimed to identify and critique patient-reported outcome measure (PROM) and patient-reported experience measure (PREM) instruments related to CVADs.
A systematic review was undertaken, commencing with an electronic search of health databases (April 2022). Studies were eligible if they used a self-reporting instrument (questionnaire) to quantitatively measure patient-reported outcomes and experiences related to CVADs (English only). Using a piloted data-extraction tool, two authors independently identified studies for full review, data extraction, and quality assessment. Data were synthesised narratively.
The search yielded 875 titles, of which 41 met the inclusion and no exclusion criteria. Of these, 31 reported results of purpose-built questionnaires; a further six reported results of generic measures used for CVADs; four included both purpose-built and generic measures. Overall study quality was low; only two studies evaluated both content validity and internal consistency. In total, 155 unique PROM items (across 27 studies) were extracted which encompassed five domains (e.g., 'Instrumental activities of daily living'; 'Pain and discomfort'). Similarly, 184 unique PREMs (from 31 studies) included 13 domains (e.g., 'Shared decision-making'; 'Education').
Increasingly, research and quality improvement studies about CVADs are incorporating PROM and PREM. These measures are largely purpose-built, however, and their validity and reliability have not been sufficiently established for use.
Prospectively submitted to the International prospective register of systematic reviews (PROSPERO) 05 July 2020.
接受实体瘤和血液系统恶性肿瘤治疗的患者以及其他急性和慢性健康状况的患者，高度依赖中央静脉通路装置（CVAD）来给予化疗和其他复杂治疗；因此，CVAD 可以对他们的健康结果和体验产生重大影响。本系统评价旨在确定和评估与 CVAD 相关的患者报告结局测量（PROM）和患者报告体验测量（PREM）工具。
进行了系统评价，从 2022 年 4 月开始对健康数据库进行电子搜索。如果研究使用自我报告工具（问卷）定量测量与 CVAD 相关的患者报告结局和体验，则符合纳入标准（仅英语）。两位作者使用经过试验的资料提取工具，独立确定进行全面审查、资料提取和质量评估的研究。资料以叙述性方式综合。
搜索产生了 875 个标题，其中 41 个符合纳入和无排除标准。其中，31 个报告了专用问卷的结果；另有 6 个报告了用于 CVAD 的通用措施的结果；4 个研究包括专用和通用措施。总体研究质量较低；只有两项研究评估了内容效度和内部一致性。总共提取了 155 个独特的 PROM 项目（来自 27 项研究），涵盖了五个领域（例如，“日常生活的工具性活动”；“疼痛和不适”）。同样，从 31 项研究中提取了 184 个独特的 PREM，其中包括 13 个领域（例如，“共同决策”；“教育”）。
越来越多的关于 CVAD 的研究和质量改进研究正在纳入 PROM 和 PREM。这些措施主要是专用的，但是它们的有效性和可靠性尚未得到充分确立，无法使用。
2020 年 7 月 5 日向国际前瞻性系统评价登记册（PROSPERO）提交了前瞻性注册。
